Ahmet Gül

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1542236/publications.pdf

Version: 2024-02-01

274 papers 14,919 citations

20817 60 h-index 117 g-index

278 all docs

278 docs citations

278 times ranked 11694 citing authors

| # | Article | IF | Citations |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Immunosuppressive therapy in lupus nephritis: The Euroâ€Lupus Nephritis Trial, a randomized trial of lowâ€dose versus highâ€dose intravenous cyclophosphamide. Arthritis and Rheumatism, 2002, 46, 2121-2131. | 6.7 | 849 |
| 2 | Familial Mediterranean Fever (FMF) in Turkey. Medicine (United States), 2005, 84, 1-11. | 1.0 | 651 |
| 3 | EULAR recommendations for the management of Behcet disease. Annals of the Rheumatic Diseases, 2008, 67, 1656-1662. | 0.9 | 624 |
| 4 | Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nature Genetics, 2010, 42, 698-702. | 21,4 | 595 |
| 5 | Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73. | 21.4 | 513 |
| 6 | The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the Rheumatic Diseases, 2010, 69, 61-64. | 0.9 | 508 |
| 7 | Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nature Genetics, 2013, 45, 202-207. | 21.4 | 483 |
| 8 | 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213225. | 0.9 | 442 |
| 9 | Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919. | 27.0 | 327 |
| 10 | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from longâ€term followup of patients in the Euroâ€Lupus Nephritis Trial. Arthritis and Rheumatism, 2004, 50, 3934-3940. | 6.7 | 325 |
| 11 | Prevalence of Behçet's disease in Istanbul, Turkey. International Journal of Dermatology, 2003, 42, 803-806. | 1.0 | 310 |
| 12 | Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032. | 0.9 | 300 |
| 13 | Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology, 2007, 46, 736-741. | 1.9 | 292 |
| 14 | Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in beh§et's disease: An openâ€label trial. Arthritis and Rheumatism, 2005, 52, 2478-2484. | 6.7 | 289 |
| 15 | Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity, 2017, 47, 183-198.e6. | 14.3 | 245 |
| 16 | Interleukin- $1\hat{1}^2$ -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh§et's disease: an open-label pilot study. Annals of the Rheumatic Diseases, 2012, 71, 563-566. | 0.9 | 212 |
| 17 | Behçets Disease as an Autoinflammatory Disorder. Inflammation and Allergy: Drug Targets, 2005, 4, 81-83. | 3.1 | 210 |
| 18 | Rare diseases bullet 12: Pulmonary manifestations of Behcet's disease. Thorax, 2001, 56, 572-578. | 5.6 | 208 |

| # | Article | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | COVIDâ€19 is a Real Headache!. Headache, 2020, 60, 1415-1421. | 3.9 | 204 |
| 20 | Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1133-1138. | 0.9 | 186 |
| 21 | 'MHC-I-opathy'â€"unified concept for spondyloarthritis and Behçet disease. Nature Reviews Rheumatology, 2015, 11, 731-740. | 8.0 | 183 |
| 22 | Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the Rheumatic Diseases, 2011, 70, 2095-2102. | 0.9 | 182 |
| 23 | A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735. | 0.9 | 176 |
| 24 | Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947. | 0.9 | 175 |
| 25 | Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Annals of the Rheumatic Diseases, 2009, 68, 1528-1534. | 0.9 | 166 |
| 26 | Familial aggregation of Behcet's disease in Turkey. Annals of the Rheumatic Diseases, 2000, 59, 622-625. | 0.9 | 164 |
| 27 | Targeted resequencing implicates the familial Mediterranean fever gene <i>MEFV</i> and the toll-like receptor 4 gene <i>TLR4</i> in Behçet disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8134-8139. | 7.1 | 140 |
| 28 | <i>HLA-DRB1*11</i> i>and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975. | 7.1 | 139 |
| 29 | Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. Nature Genetics, 2017, 49, 438-443. | 21.4 | 129 |
| 30 | CT findings of pulmonary artery aneurysms during treatment for BehÃSet's disease American Journal of Roentgenology, 1999, 172, 729-733. | 2.2 | 126 |
| 31 | Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8867-8872. | 7.1 | 123 |
| 32 | Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913. | 0.9 | 123 |
| 33 | Immunohistology of skin pathergy reaction in Behçet's disease. British Journal of Dermatology, 1995, 132, 901-907. | 1.5 | 121 |
| 34 | Immunology and functional genomics of Beh�et's disease. Cellular and Molecular Life Sciences, 2003, 60, 1903-1922. | 5.4 | 117 |
| 35 | Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Annals of the Rheumatic Diseases, 2018, 77, 1558-1565. | 0.9 | 114 |
| 36 | Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Seminars in Arthritis and Rheumatism, 2017, 47, 115-120. | 3.4 | 108 |

| # | Article | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 37 | Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Seminars in Immunopathology, 2015, 37, 413-418. | 6.1 | 107 |
| 38 | COAGULATION FACTOR V GENE MUTATION INCREASES THE RISK OF VENOUS THROMBOSIS IN BEHÃ \pm ET'S DISEASE. Rheumatology, 1996, 35, 1178-1180. | 1.9 | 102 |
| 39 | Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: confirmed specificity but decreased sensitivity with sharp needles Annals of the Rheumatic Diseases, 1993, 52, 823-825. | 0.9 | 100 |
| 40 | Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis and Rheumatism, 2005, 52, 1836-1842. | 6.7 | 100 |
| 41 | Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus, 2004, 13, 274-278. | 1.6 | 90 |
| 42 | Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. Nature Immunology, 2020, 21, 857-867. | 14.5 | 90 |
| 43 | Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. Rheumatology, 2018, 57, 2200-2212. | 1.9 | 89 |
| 44 | Adult-onset still's disease. International Journal of Clinical Practice, 2009, 63, 1050-1055. | 1.7 | 88 |
| 45 | Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. British Journal of Rheumatology, 2003, 42, 860-864. | 2.3 | 87 |
| 46 | Evidence for linkage of the HLA-B locus in Beh�et's disease, obtained using the transmission disequilibrium test. Arthritis and Rheumatism, 2001, 44, 239-241. | 6.7 | 86 |
| 47 | HLA-B*51 and Behçet Disease. Ocular Immunology and Inflammation, 2012, 20, 37-43. | 1.8 | 86 |
| 48 | Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet Uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1169-1177. | 1.9 | 84 |
| 49 | International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108. | 1.9 | 84 |
| 50 | Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Research and Therapy, 2015, 17, 243. | 3.5 | 83 |
| 51 | Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Annals of the Rheumatic Diseases, 2016, 75, 1051-1056. | 0.9 | 83 |
| 52 | Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocular Immunology and Inflammation, 2018, 26, 1023-1033. | 1.8 | 82 |
| 53 | Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center. Journal of Rheumatology, 2014, 41, 1304-1310. | 2.0 | 75 |
| 54 | International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor–Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586. | 3.4 | 75 |

| # | Article | IF | Citations |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Genetics of Behçet's disease. Current Opinion in Rheumatology, 2014, 26, 56-63. | 4.3 | 70 |
| 56 | Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatology International, 2012, 32, 3277-3279. | 3.0 | 68 |
| 57 | Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatology International, 2012, 32, 177-182. | 3.0 | 68 |
| 58 | Lack of association of HLA-B*51 with a severe disease course in Behcet's disease. British Journal of Rheumatology, 2001, 40, 668-672. | 2.3 | 67 |
| 59 | Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. Journal of Rheumatology, 2016, 43, 524-529. | 2.0 | 67 |
| 60 | Linkage mapping of a novel susceptibility locus for Behiʻʻz½et's disease to chromosome 6p22-23. Arthritis and Rheumatism, 2001, 44, 2693-2696. | 6.7 | 63 |
| 61 | Peripheral blood T cell expansions in patients with Behcet's disease. Clinical and Experimental Immunology, 1997, 107, 520-527. | 2.6 | 63 |
| 62 | Perinatal Outcomes in Severe Preeclampsia-Eclampsia with and without HELLP Syndrome. Gynecologic and Obstetric Investigation, 2005, 59, 113-118. | 1.6 | 62 |
| 63 | A weak association of HLA-B*2702 with Behçet's disease. Genes and Immunity, 2002, 3, 368-372. | 4.1 | 61 |
| 64 | A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. Annals of the Rheumatic Diseases, 2016, 75, 2208-2211. | 0.9 | 59 |
| 65 | Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatology International, 2012, 32, 79-83. | 3.0 | 58 |
| 66 | Association of familial Mediterranean fever–related <i>MEFV</i> variations with ankylosing spondylitis. Arthritis and Rheumatism, 2010, 62, 3232-3236. | 6.7 | 57 |
| 67 | FMF50: a score for assessing outcome in familial Mediterranean fever. Annals of the Rheumatic Diseases, 2014, 73, 897-901. | 0.9 | 57 |
| 68 | Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 752-762. | 3.4 | 56 |
| 69 | Pro-inflammatory cellular immune response in Behçet's disease. Rheumatology International, 2007, 27, 1113-1118. | 3.0 | 54 |
| 70 | Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association?. Journal of Neurology, 2006, 253, 928-934. | 3.6 | 53 |
| 71 | Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Behçet's Disease in Turkey. Japanese Journal of Ophthalmology, 2007, 51, 431-436. | 1.9 | 53 |
| 72 | Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study. Ocular Immunology and Inflammation, 2017, 25, 62-70. | 1.8 | 52 |

| # | Article | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14405-14411. | 7.1 | 52 |
| 74 | Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine, 2008, 75, 299-302. | 1.6 | 50 |
| 75 | Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatology International, 2011, 31, 183-189. | 3.0 | 50 |
| 76 | Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology, 1999, 38, 1298-1299. | 1.9 | 48 |
| 77 | Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcl§et's disease. Rheumatology, 2005, 44, 614-617. | 1.9 | 47 |
| 78 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus, 2016, 25, 177-184. | 1.6 | 47 |
| 79 | Perinatal Outcomes of Twin Pregnancies Discordant for Major Fetal Anomalies. Fetal Diagnosis and Therapy, 2005, 20, 244-248. | 1.4 | 44 |
| 80 | Organizing pneumonia associated with pulmonary artery aneurysms in Behçet's disease. Rheumatology, 1999, 38, 1285-1289. | 1.9 | 42 |
| 81 | A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatology International, 2005, 25, 442-446. | 3.0 | 41 |
| 82 | Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. Journal of Rheumatology, 2017, 44, 619-625. | 2.0 | 41 |
| 83 | <i>IL1RN</i> Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€I Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330. | 5.6 | 40 |
| 84 | Familial Mediterranean Fever and Seronegative Arthritis. Current Rheumatology Reports, 2011, 13, 388-394. | 4.7 | 39 |
| 85 | Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. International Journal of Clinical Practice, 2005, 59, 777-781. | 1.7 | 38 |
| 86 | Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clinical Rheumatology, 2005, 24, 673-676. | 2.2 | 38 |
| 87 | The regulation of MEFV expression and its role in health and familial Mediterranean fever. Genes and Immunity, 2011, 12, 497-503. | 4.1 | 37 |
| 88 | Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 133-140. | 3.0 | 35 |
| 89 | Standard and Novel Therapeutic Approaches to Behçet's Disease. Drugs, 2007, 67, 2013-2022. | 10.9 | 35 |
| 90 | Association of the MEFV Gene Variations With Inflammatory Bowel Disease in Turkey. Journal of Clinical Gastroenterology, 2013, 47, e23-e27. | 2.2 | 35 |

| # | Article | IF | Citations |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease. Clinical Rheumatology, 1996, 15, 207-210. | 2.2 | 34 |
| 92 | Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. Journal of Rheumatology, 2015, 42, 2465-2469. | 2.0 | 33 |
| 93 | Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations. European Journal of Human Genetics, 2015, 23, 678-687. | 2.8 | 33 |
| 94 | Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Practice and Research in Clinical Rheumatology, 2016, 30, 296-303. | 3.3 | 33 |
| 95 | Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937. | 2.0 | 33 |
| 96 | Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behçet's Disease. Annals of Pharmacotherapy, 2004, 38, 808-811. | 1.9 | 32 |
| 97 | Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatology International, 2010, 30, 1459-1463. | 3.0 | 31 |
| 98 | Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients. Journal of Rheumatology, 2010, 37, 374-378. | 2.0 | 31 |
| 99 | Expression of regulatory receptors on $\hat{I}^3\hat{I}$ T Cells and their cytokine production in Behcet's disease. Arthritis Research and Therapy, 2013, 15, R15. | 3.5 | 31 |
| 100 | Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. International Journal of Clinical Practice, 2004, 58, 1003-1007. | 1.7 | 30 |
| 101 | Expression of KIR and C-type lectin receptors in Behcet's disease. British Journal of Rheumatology, 2004, 43, 423-427. | 2.3 | 29 |
| 102 | HSP 60 expression in recurrent oral ulcerations of Behçet's disease. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 110, 196-200. | 1.4 | 29 |
| 103 | Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis. , 2019, 60, 52. | | 29 |
| 104 | Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808. | 1.9 | 29 |
| 105 | Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatology International, 2005, 25, 211-214. | 3.0 | 28 |
| 106 | Predicting Important Residues and Interaction Pathways in Proteins Using Gaussian Network Model: Binding and Stability of HLA Proteins. PLoS Computational Biology, 2010, 6, e1000845. | 3.2 | 28 |
| 107 | Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clinical Rheumatology, 2007, 26, 1913-1915. | 2.2 | 27 |
| 108 | An Algorithm for the Diagnosis of Beh $\tilde{\text{A}}$ §et Disease Uveitis in Adults. Ocular Immunology and Inflammation, 2021, 29, 1154-1163. | 1.8 | 26 |

| # | Article | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|
| 109 | Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Beh \tilde{A} disease. Journal of Neuroimmunology, 2011, 239, 91-97. | 2.3 | 25 |
| 110 | Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1750-1753. | 2.0 | 25 |
| 111 | Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201. | 2.0 | 24 |
| 112 | Reâ€evaluation of heterogeneity in HLAâ€B*510101 associated with Behçet's disease. Tissue Antigens, 200-72, 347-353. | 8,1.0 | 23 |
| 113 | Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 457-465. | 1.9 | 22 |
| 114 | Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. Arthritis and Rheumatism, 2007, 56, 345-350. | 6.7 | 21 |
| 115 | Core Set of Domains for Outcome Measures in Behçet's Syndrome. Arthritis Care and Research, 2022, 74, 691-699. | 3.4 | 21 |
| 116 | Low-dose natural human interferon- \hat{l}_{\pm} lozenges in the treatment of Behçet's syndrome. Rheumatology, 2009, 48, 1388-1391. | 1.9 | 20 |
| 117 | Comparison of perinatal and maternal outcomes of severe preeclampsia, eclampsia, and HELLP syndrome. Journal of the Turkish German Gynecology Association, 2011, 12, 90-96. | 0.6 | 20 |
| 118 | Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener?s granulomatosis. Clinical Rheumatology, 2003, 22, 333-335. | 2.2 | 19 |
| 119 | Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening. Scandinavian Journal of Gastroenterology, 2014, 49, 1414-1418. | 1.5 | 19 |
| 120 | Dynamics of Inflammatory Response in Autoinflammatory Disorders: Autonomous and Hyperinflammatory States. Frontiers in Immunology, 2018, 9, 2422. | 4.8 | 19 |
| 121 | Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. Rheumatology International, 2020, 40, 1903-1910. | 3.0 | 19 |
| 122 | Distribution of Common CARD15 Variants in Patients with Sporadic Crohn's Disease: Cases from Turkey. Digestive Diseases and Sciences, 2006, 51, 706-710. | 2.3 | 18 |
| 123 | Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis. Rheumatology International, 2013, 33, 733-741. | 3.0 | 18 |
| 124 | Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. Journal of Rheumatology, 2015, 42, 2436-2441. | 2.0 | 18 |
| 125 | Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. Lupus, 1996, 5, 120-122. | 1.6 | 17 |
| 126 | No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet's disease. Clinical Rheumatology, 2009, 28, 1385-1388. | 2.2 | 17 |

| # | Article | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 226-231. | 3.0 | 17 |
| 128 | Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. Journal of Neuroimmunology, 2013, 263, 139-144. | 2.3 | 17 |
| 129 | Treatment of familial Mediterranean fever: colchicine and beyond. Israel Medical Association Journal, 2014, 16, 281-4. | 0.1 | 17 |
| 130 | Recovery from hypoxia and hypercapnic hypoxia: Impacts on the transcription of key antioxidants in the shrimp Litopenaeus vannamei. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2014, 170, 43-49. | 1.6 | 16 |
| 131 | An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436. | 2.0 | 16 |
| 132 | The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response. International Journal of Infectious Diseases, 2021, 105, 756-762. | 3.3 | 16 |
| 133 | Increased IL-23 receptor, TNF-α and IL-6 expression in individuals with the IL23R–IL12RB2 locus polymorphism. Immunology Letters, 2014, 160, 96-98. | 2.5 | 15 |
| 134 | Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease. Genes and Immunity, 2016, 17, 396-399. | 4.1 | 15 |
| 135 | Amyopathic Dermatomyositis Associated with Cervical Cancer. Clinical Rheumatology, 2001, 20, 438-440. | 2.2 | 14 |
| 136 | Generation of integration-free induced pluripotent stem cells from a patient with Familial Mediterranean Fever (FMF). Stem Cell Research, 2015, 15, 694-696. | 0.7 | 14 |
| 137 | Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clinical Rheumatology, 2012, 31, 325-328. | 2.2 | 13 |
| 138 | HLA-B51 negative monozygotic twins discordant for Behcet's disease. Rheumatology, 1997, 36, 922-923. | 1.9 | 12 |
| 139 | The Use of Two Different Health Assessment Questionnaires in Turkish Rheumatoid Arthritis Population and Assessment of the Associations with Disability. Clinical Rheumatology, 1999, 18, 33-37. | 2.2 | 12 |
| 140 | TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatology International, 2011, 31, 1147-1151. | 3.0 | 12 |
| 141 | Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. Rheumatology International, 2015, 35, 1473-1478. | 3.0 | 12 |
| 142 | Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group. British Journal of Rheumatology, 1998, 37, 1126-1128. | 2.3 | 11 |
| 143 | Colchicine-Induced Myopathy in a Teenager with Familial Mediterranean Fever. Annals of Pharmacotherapy, 2003, 37, 1821-1824. | 1.9 | 11 |
| 144 | Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-18. | 1.3 | 11 |

| # | Article | IF | Citations |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102332. | 2.0 | 11 |
| 146 | Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. Lupus, 2020, 29, 379-388. | 1.6 | 11 |
| 147 | Natural killer cells dominate a Th-1 polarized response in Behçet's disease patients with uveitis. Clinical and Experimental Rheumatology, 2015, 33, S24-9. | 0.8 | 11 |
| 148 | Genome-wide association studies in Behçet's disease: expectations and promises. Clinical and Experimental Rheumatology, 2011, 29, S3-5. | 0.8 | 10 |
| 149 | Clinical course of abdominal aortic aneurysms in Behçet disease: a retrospective analysis. Rheumatology International, 2019, 39, 1061-1067. | 3.0 | 9 |
| 150 | Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2009, 29, 365-370. | 3.0 | 8 |
| 151 | MEFV gene variations in patients with systemic lupus erythematosus. Modern Rheumatology, 2014, 24, 93-96. | 1.8 | 8 |
| 152 | Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. Lupus, 2019, 28, 1480-1487. | 1.6 | 8 |
| 153 | Molecular dynamics simulations provide molecular insights into the role of HLAâ€B51 in Behçet's disease pathogenesis. Chemical Biology and Drug Design, 2020, 96, 644-658. | 3.2 | 8 |
| 154 | Inflammatory status might direct ILC and NK cells to IL-17 expressing ILC3 and NK subsets in Behcet's disease. Immunology Letters, 2021, 235, 1-8. | 2.5 | 8 |
| 155 | IL-17A and IFN-γ are Up-regulated in CD4 and γδT Cells in Active Behcet's Disease Patients. Immunology Letters, 2022, 242, 37-45. | 2.5 | 8 |
| 156 | Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. Clinical Rheumatology, 2016, 35, 2495-2499. | 2.2 | 7 |
| 157 | Budd–Chiari syndrome in Behçet's disease: a retrospective multicenter study. Clinical Rheumatology, 2021, , 1. | 2.2 | 7 |
| 158 | Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 77-82. | 0.8 | 7 |
| 159 | Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 142-146. | 0.8 | 7 |
| 160 | Clinical course of ocular Behçet's disease in siblings. Ocular Immunology and Inflammation, 2001, 9, 111-124. | 1.8 | 6 |
| 161 | Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatology International, 2005, 26, 16-20. | 3.0 | 6 |
| 162 | Recurrent anterior uveitis in Henoch Schonlein's vasculitis. Rheumatology International, 2010, 30, 1377-1379. | 3.0 | 6 |

| # | Article | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 163 | Comment on the article by Durmus et al. "Clinical significance of MEFV mutations in ankylosing spondylitisâ€. Joint Bone Spine, 2010, 77, 281. | 1.6 | 6 |
| 164 | Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. Journal of Thrombosis and Thrombolysis, 2021, 51, 466-474. | 2.1 | 6 |
| 165 | Psychometric validation of Barkley's Adult Sluggish Cognitive Tempo (SCT) Ratings Scale -Turkish version and distinguishing SCT from attention deficit-hyperactivity disorder (ADHD) among Turkish adults. Research in Developmental Disabilities, 2022, 121, 104155. | 2.2 | 6 |
| 166 | An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2004, 38, 1320-1321. | 1.9 | 5 |
| 167 | Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus, 2022, 31, 433-442. | 1.6 | 5 |
| 168 | Rosai–Dorfman disease with factor XII deficiency. Clinical Rheumatology, 2009, 28, 733-736. | 2.2 | 4 |
| 169 | Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. Rheumatology International, 2022, 42, 457-467. | 3.0 | 4 |
| 170 | Genetics of Behçet's Disease. , 2010, , 265-276. | | 4 |
| 171 | Improvement of Libman-Sacks endocarditis after combination of warfarin and immunosuppressive therapy. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 687-690. | 0.5 | 4 |
| 172 | Frequency and severity of COVIDâ€19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. Journal of Medical Virology, 2022, 94, 3431-3437. | 5.0 | 4 |
| 173 | Effect of different cytokines in combination with IL-15 on the expression of activating receptors in NK cells of patients with Behçet's disease. Immunologic Research, 2022, 70, 654-666. | 2.9 | 4 |
| 174 | Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2008, 28, 959-964. | 3.0 | 3 |
| 175 | Prenatal Diagnosis of Bilateral Ventriculocoronary Fistulas With Hypoplasia of the Left Ventricle. Journal of Ultrasound in Medicine, 2008, 27, 1111-1116. | 1.7 | 3 |
| 176 | Comparison of argon laser photocoagulation-induced cutaneous inflammation and skin pathergy test in Behçet's disease. Clinical Rheumatology, 2010, 29, 59-63. | 2.2 | 3 |
| 177 | Cost of Familial Mediterranean Fever (Fmf) Disease In Turkey. Value in Health, 2015, 18, A666. | 0.3 | 3 |
| 178 | FRIO479â€Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis. Annals of the Rheumatic Diseases, 2016, 75, 611.3-612. | 0.9 | 3 |
| 179 | Behçet Disease. , 2019, , 647-665. | | 3 |
| 180 | POS1257â€HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 912-913. | 0.9 | 3 |

| # | Article | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 181 | A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. Turkish Journal of Medical Sciences, 2021, 51, 2243-2247. | 0.9 | 3 |
| 182 | Pseudodominance of autoinflammatory disease in a single Turkish family explained by co-inheritance of haploinsufficiency of A20 and familial Mediterranean fever. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 89-92. | 0.8 | 3 |
| 183 | A novel TNFRSF1 gene mutation in a Turkish family: a report of three cases. Clinical Rheumatology, 2013, 32, 83-85. | 2.2 | 2 |
| 184 | Prenatal diagnosis and postnatal outcome of persistent right ductus arteriosus: a report of three cases. Journal of Medical Ultrasonics (2001), 2015, 42, 571-574. | 1.3 | 2 |
| 185 | The rate and significance of type 1/type 2 serum amyloid A protein gene polymorphisms in patients with ankylosing spondylitis and amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 207-208. | 3.0 | 2 |
| 186 | FRIO502â€Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab. Annals of the Rheumatic Diseases, 2016, 75, 620.1-620. | 0.9 | 2 |
| 187 | Binding stability of peptides on major histocompatibility complex class I proteins: role of entropy and dynamics. Physical Biology, 2018, 15, 026005. | 1.8 | 2 |
| 188 | THU0303â€THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÇET'S SYNDROME. , 2019, , . | | 2 |
| 189 | Letter: is pneumococcal vaccination safe during the COVIDâ€19 pandemic?. Alimentary Pharmacology and Therapeutics, 2020, 52, 919-920. | 3.7 | 2 |
| 190 | Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. Rheumatology International, 2021, 41, 439-448. | 3.0 | 2 |
| 191 | A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. Rheumatology International, 2021, 41, 1667-1672. | 3.0 | 2 |
| 192 | Reinfection with SARSâ€CoVâ€2 in a kidney transplant recipient. Transplant Infectious Disease, 2021, 23, e13695. | 1.7 | 2 |
| 193 | A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 39-42. | 1.6 | 2 |
| 194 | Faible fréquence d'HLA-B27 chez des patients atteints de spondylarthrite ankylosante en Turquie. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 433-437. | 0.0 | 1 |
| 195 | THU0203â€Cross-sectional assessment of damage in takayasu arteritis with a validated tool. Annals of the Rheumatic Diseases, 2013, 71, 224.1-224. | 0.9 | 1 |
| 196 | THU0195â€Consistent efficacy and safety of tofacitinib in rheumatoid arthritis patients with inadequate response or intolerance to NON-MTX csdmards. , 2017, , . | | 1 |
| 197 | AB0766â€SUCCESSFUL TEATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 1409.3-1410. | 0.9 | 1 |
| 198 | Molecular Diagnosis Experience in Familial Mediterranean Fever: The Most Frequent Mutations in the MEFV Gene. Haseki Tip Bulteni, 2018, 56, 42-49. | 0.3 | 1 |

| # | Article | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 199 | FRI0675â€Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf alpha biological therapy for rheumatoid arthritis patients. , 2018, , . | | 1 |
| 200 | The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus, 2022, 31, 555-564. | 1.6 | 1 |
| 201 | Genetic heterogeneity in familial Mediterranean fever: Comment on the article by Cazeneuve et al. Arthritis and Rheumatism, 2004, 50, 1355-1355. | 6.7 | 0 |
| 202 | A novel TNFRSF1 gene mutation in a turkish family: report of three cases. Annals of the Rheumatic Diseases, 2010, 69, A31-A31. | 0.9 | 0 |
| 203 | Correction: Predictors of damage and survival in patients with Wegener's granulomatosis: Analysis of 50 patients Journal of Rheumatology, 2010, 37, 1551.2-1551. | 2.0 | 0 |
| 204 | PMS37 Productivity Loss of Ankylosing Spondylitis Patients in Turkey Due to Sick Leave. Value in Health, 2012, 15, A40. | 0.3 | 0 |
| 205 | MEFV gene variations in patients with systemic lupus erythematosus. Modern Rheumatology, 2013, , 1. | 1.8 | 0 |
| 206 | Ankylosing Spondylitis Health Care Costs And Associated Disease Activity Scores In Turkey. Value in Health, 2013, 16, A222. | 0.3 | 0 |
| 207 | Comparison of ultraviolet B-induced cutaneous inflammation and skin pathergy test in Behçet's disease. International Journal of Clinical Rheumatology, 2013, 8, 205-211. | 0.3 | 0 |
| 208 | FRIO210â€Poor immunization with hepatitis B vaccination in patients with granulomatosis with poliangiitis (wegener's) and more favorable antibody response in females. Annals of the Rheumatic Diseases, 2013, 71, 385.1-385. | 0.9 | 0 |
| 209 | FRIO442â€Acute Phase Reactants and their Correlation with Clinical Activity in Behcet's Disease. Annals of the Rheumatic Diseases, 2014, 73, 547.1-547. | 0.9 | 0 |
| 210 | AB0595â€Favourable Renal Outcome in AAV Nephritis: A CASE Series Reported from A Tertiary Referral Center. Annals of the Rheumatic Diseases, 2014, 73, 1002.1-1002. | 0.9 | 0 |
| 211 | THU0360â€Small Bowel Mucosal Findings in Familial Mediterranean Fever. Annals of the Rheumatic Diseases, 2014, 73, 307.1-307. | 0.9 | 0 |
| 212 | OPO119â€Patient Journey and Treatment Route to Use of First Biologic in Rare Autoinflammatory Diseases: an International Retrospective Chart Review. Annals of the Rheumatic Diseases, 2014, 73, 106.1-106. | 0.9 | 0 |
| 213 | AB0633â€A Very High Prevalance of Avascular Necrosis in Turkish Patients with Granulomatosis with Polyangiitis (Wegener's): Preliminary Results from a Single Centre: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 1110.3-1111. | 0.9 | 0 |
| 214 | THU0561â€Salivary IL-1 Alpha and IL-1 Beta Levels Associated with Oral Mucosal Disease Activity in Behcet's Disease: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 403.3-404. | 0.9 | 0 |
| 215 | FRIO279â€High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort:. Annals of the Rheumatic Diseases, 2015, 74, 525.3-526. | 0.9 | 0 |
| 216 | AB1118â€Validity and Reliability of Medication Adherence Scale in FMF (Adult Version). Annals of the Rheumatic Diseases, 2015, 74, 1274.3-1275. | 0.9 | 0 |

| # | Article | IF | Citations |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 217 | Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF. Pediatric Rheumatology, 2015, 13, . | 2.1 | 0 |
| 218 | Reply to Stoimenis et al. European Journal of Human Genetics, 2015, 23, 1280-1280. | 2.8 | 0 |
| 219 | MATHEMATICAL MODELING OF BEHÇET'S DISEASE: A DYNAMICAL SYSTEMS APPROACH. Journal of Biological Systems, 2015, 23, 231-257. | 1.4 | 0 |
| 220 | FRIO245â€Lung Damage in ANCA Associated Vasculitis Assessed by Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 513.2-513. | 0.9 | 0 |
| 221 | AB0433â€Disease Characteristics, Survival Analysis and Mortality in A Single Centre Cohort of 240 Patients with Antiphospholipid Syndrome. Annals of the Rheumatic Diseases, 2016, 75, 1055.2-1055. | 0.9 | 0 |
| 222 | AB0896â€Cogan Syndrome: Differential Response To Biologic Agents and Role of PET-CT in The Increased Diagnosis of Aortitis. Annals of the Rheumatic Diseases, 2016, 75, 1208.3-1209. | 0.9 | 0 |
| 223 | SAT0295â€Autoimmune Hemolytic Anemia and Thrombocytopenia in A Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey: Clinical Associations and Effect on Disease Damage and Survival. Annals of the Rheumatic Diseases, 2016, 75, 775.1-775. | 0.9 | 0 |
| 224 | Behçet's disease (or syndrome) –Âan update. Revue De Medecine Interne, 2017, 38, A8-A9. | 1.0 | 0 |
| 225 | OP0063â€Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40., 2017,,. | | 0 |
| 226 | THU0329â€Budd-chiari syndrome in behÇet's disease: a retrospective multicenter study. , 2017, , . | | 0 |
| 227 | The association between P selectin glycoprotein ligand 1 gene variable number of tandem repeats polymorphism and risk of thrombosis in Behçet's disease. International Journal of Rheumatic Diseases, 2018, 21, 2175-2179. | 1.9 | O |
| 228 | Behçet Disease. , 2018, , 365-370. | | 0 |
| 229 | AB0524â€SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMİC LUPUS ERYTHEMATOSUS (SLE PROSPECTIVE FOLLOW-UP STUDY. , 2019, , . |): A | 0 |
| 230 | 281â€Lupus nephritis biomarkers. , 2019, , . | | 0 |
| 231 | SAT0184 \hat{a} \in ASSOCIATION OF SERUM AND URINE LEVELS OF TWEAK, MCP-1 AND NGAL WITH DISEASE ACTIVITY SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , . | Y IN | 0 |
| 232 | P26â€Serum BAFF and APRIL as candidate biomarkers in systemic lupus erythematosus (SLE): a prospective follow-up study. , 2020, , . | | 0 |
| 233 | P69 Risk factors for adverse pregnancy outcome in patients with SLE. , 2020, , . | | 0 |
| 234 | P73â€The relationship between pregnancy, disease activity and adverse pregnancy outcomes in systemic lupus erythematosus. , 2020, , . | | 0 |

| # | Article | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------|
| 235 | P181â€Comparison of SLEDAI-2K and SLEDAI-2KG (glucocorticoid) indexes in patients with systemic lupus erythematosus (SLE). , 2020, , . | | 0 |
| 236 | P9â€Validation of the adjusted global antiphospholipid syndrome score and correlation with extra-criteria manifestations. , 2020, , . | | 0 |
| 237 | mRNA Expression Levels of NKp30, NKp46, NKG2D, Perforin and Granzyme in the Behçet's Disease. Turkish Journal of Immunology, 2021, , . | 0.1 | O |
| 238 | POS0142â€MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ASSOCIATED FACTORS: REAL LIFE DATA FROM A SINGLE CENTER. Annals of the Rheumatic Diseases, 2021, 80, 282.3-283. | 0.9 | 0 |
| 239 | ABO448â€SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1251.2-1252. | 0.9 | O |
| 240 | POS1339â€MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER. Annals of the Rheumatic Diseases, 2021, 80, 951.3-952. | 0.9 | 0 |
| 241 | AB0653â€COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSU Annals of the Rheumatic Diseases, 2021, 80, 1359.1-1359. | IS. 0.9 | O |
| 242 | POS0706â€PERFORMANCES OF DIFFERENT CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN A SINGLE CENTER COHORT FROM TURKEY. Annals of the Rheumatic Diseases, 2021, 80, 602.1-603. | S _{0.9} | 0 |
| 243 | POS0766â€CLUSTER ANALYSIS AND COMPARISON OF CUMULATIVE DAMAGE BY DIAPS IN A SINGLE CENTER COHORT OF APS PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 636.2-637. | 0.9 | O |
| 244 | POS1259â€FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS. Annals of the Rheumatic Diseases, 2021, 80, 913.2-914. | 0.9 | 0 |
| 245 | POS1445â€RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS. Annals of the Rheumatic Diseases, 2021, 80, 1006.2-1007. | 0.9 | O |
| 246 | AB0331â€PULMONARY INVOLVEMENT IN A SINGLE CENTER COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases, 2021, 80, 1191.1-1191. | 0.9 | 0 |
| 247 | POS0710â€ANALYSIS OF 5-YEAR HOSPITALIZATION DATA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOS DAMAGE IS A RISK FACTOR FOR FREQUENT AND LONGER STAYS. Annals of the Rheumatic Diseases, 2021, 80, 604.2-605. | US: 0.9 | O |
| 248 | OP0313â€PRELIMINARY CRITERIA FOR MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH CORONAVII DISEASE-19. Annals of the Rheumatic Diseases, 2021, 80, 191.1-192. | R <u>US</u> | 0 |
| 249 | AB0369â€EVALUATION OF BASELINE POSITRON EMISSION TOMOGRAPHY IN THE DIAGNOSIS AND ASSESSMEN OF GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases, 2021, 80, 1210.2-1211. | √ _{0.9} | O |
| 250 | Pulmonary Complications of Behçet's Disease. Lung Biology in Health and Disease, 2005, , 377-396. | 0.1 | 0 |
| 251 | SAT0343â€Utility of Vascular Findings by PET/CT Scan in The Diagnosis and Activity Assessment of Takayasu Arteritis. Annals of the Rheumatic Diseases, 2016, 75, 791.2-791. | 0.9 | O |
| 252 | FRIO441â€Idiopathic inflammatory myopathies: clinical characteristics, survivial and poor prognostic factors of 110 patients from turkey. , 2018, , . | | 0 |

| # | Article | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------|
| 253 | SAT0489â€Assesment of persistent organ damage according to imacs (INTERNATIONAL MYOSITIS) Tj ETQq1 1 0 myositis. , 2018, , . | 0.784314 | rgBT /Over |
| 254 | SAT0597â€New autoinflammatory phenotype manifesting as hypocomplementemic urticarial vasculitis and associated with homozygous agbl3 variant. , 2018, , . | | 0 |
| 255 | Genetics of Behçet's Disease. , 2020, , 223-233. | | 0 |
| 256 | AB0485â€INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES. Annals of the Rheumatic Diseases, 2020, 79, 1540.2-1540. | 0.9 | 0 |
| 257 | SATO178â€HYDROXYCHLOROQUINE CONTROLS DISEASE ACTIVITY IN SLE AND MULTIMODAL IMAGING TECHNIQUES SHOULD BE USED TO DETECT OCULAR TOXICITY. Annals of the Rheumatic Diseases, 2020, 79, 1030.2-1031. | 0.9 | 0 |
| 258 | AB0486â€ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE. Annals of the Rheumatic Diseases, 2020, 79, 1540.1-1541. | 0.9 | 0 |
| 259 | ABO480â€AN OPEN-LABEL, EXPLORATORY STUDY TO ESTABLISH THE EFFICACY AND SAFETY OF 1-YEAR CANAKINUMAB TREATMENT IN BEHÇET'S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT. Annals of the Rheumatic Diseases, 2020, 79, 1537.3-1538. | 0.9 | 0 |
| 260 | FRIO160â€THE CORRELATION BETWEEN PREGNANCY, DISEASE ACTIVITY AND ADVERSE PREGNANCY OUTCOMI IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases, 2020, 79, 664.1-664. | ES 0.9 | 0 |
| 261 | SAT0261â€FEATURES AND RISK FACTORS OF SERIOUS INFECTIONS IN ANCA ASSOCIATED VASCULITIS: LONG TERM FOLLOW UP OF 186 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1073.1-1073. | 0.9 | 0 |
| 262 | THU0369â€EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY. Annals of the Rheumatic Diseases, 2020, 79, 416.1-417. | 0.9 | O |
| 263 | SATO200â€RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1042.1-1042. | 0.9 | 0 |
| 264 | SAT0346â€THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE ASSESSED BY ACTIVITY SCORES. Annals of the Rheumatic Diseases, 2020, 79, 1119.2-1119. | 0.9 | 0 |
| 265 | SATO238â€VALIDATION OF THE ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE AND CORRELATION WITH EXTRA-CRITERIA MANIFESTATIONS. Annals of the Rheumatic Diseases, 2020, 79, 1062.2-1062. | N _{0.9} | 0 |
| 266 | OP0274â€CLINICAL ASPECTS, LABORATORY CHARACTERISTICS AND TREATMENT RESPONSES OF AA AMYLOIDOSIS: SINGLE CENTER EXPERIENCE WITH 163 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 171.1-171. | 0.9 | 0 |
| 267 | THU0349â€THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 406.2-406. | 0.9 | 0 |
| 268 | AB0461â€ANCA-ASSOCIATED VASCULITIS: CLINICAL FEATURES, RELAPSE, ORGAN DAMAGE AND SURVIVAL IN 1 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1529.1-1529. | .97 0.9 | 0 |
| 269 | Cardiovascular risk in antiphospholipid syndrome: A comparison of thrombotic and obstetric disease subsets. Ulusal Romatoloji Dergisi, 2020, 12, 83-87. | 0.0 | O |
| 270 | Initial complete blood count score and predicting disease progression in COVID-19 patients. American Journal of Blood Research, 2021, 11, 77-83. | 0.6 | 0 |

Ahmet Gýl

| # | Article | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 271 | Reply to: Behçet's disease: an MHC-l-opathy?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 104, 6. | 0.8 | 0 |
| 272 | Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center. Ulusal Romatoloji Dergisi, 2021, 13, 116-120. | 0.0 | 0 |
| 273 | Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy. Ulusal Romatoloji Dergisi, 2021, 13, 100-106. | 0.0 | O |
| 274 | Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, . | 0.9 | 0 |